ClinicalTrials.gg
CompletedNCT04648969Updated Aug 26, 2026Results posted

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

A Phase 2 interventional study of kisspeptin 112-121 and GnRH in Hypogonadotropic Hypogonadism, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Stephanie B. Seminara, MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled May 2019, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.

Enrollment
121st of 154
18 · median 45
Started
2019
with 6 others
Phase 2
54 of 185
4 open now
Registered
166th of 185
by date
Lead sponsor
6 of 185
Stephanie B. Seminara, MD

Among the 185 studies in Hypogonadism with a site in United States, this one is the 121st largest by enrollment of the 154 interventional ones that give a count, is one of 7 that started in 2019, is one of 54 in phase 2, and was the 166th registered.

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

Browse Hypogonadism studies →

Open to participants now

12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Hypogonadism with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

Read the detailed description
  • Assignment: Each study subject will serve as their own control. The order of kisspeptin doses will be randomized within each set/exposure.
  • Delivery of Interventions:

    • Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. Subjects will also wear a gonadotropin releasing hormone (GnRH) pump prior to the inpatient study visit.
    • On the day of the inpatient study, the subjects will

      • Undergo q10 min blood sampling for 6 hours,
      • Receive kisspeptin intravenous (IV) boluses from hour 6 to hour 44 (20 boluses total),
      • Undergo q10 min blood samplings for another 6 hours,
      • Receive a single GnRH IV bolus at hour 51.
03

Conditions studied

  • Hypogonadotropic Hypogonadism

Browse trials for

Keywords

  • hypogonadotropic hypogonadism, kisspeptin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion/exclusion criteria:

  • Age 18 years and older,
  • Confirmed diagnosis of HH with

    • Low testosterone or estradiol,
    • Low or low-normal gonadotropin levels,
    • Thyroid stimulating hormone (TSH) and prolactin within the reference range,
    • Absence of abnormal pituitary or hypothalamic findings on Magnetic resonance imaging (MRI),
  • All other medical conditions stable and well controlled,
  • No prescription medications known to affect reproductive endocrine function for at least 2 months or for 5 half-lives of the drug (whichever is shorter) except for medications used to treat the subject's reproductive condition,
  • No history of a medication reaction requiring emergency medical care,
  • No illicit drug use,
  • No excessive alcohol consumption (\<10 drinks/week),
  • Normal blood pressure (BP), (systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg),
  • White blood cell, counts, and TSH between 90% of the lower limit and 110% of the upper limit of the reference range,
  • Prolactin below 110% of the upper limit of the reference range,
    • Women: no less than 0.5 gm/dL below the lower limit of the reference range for normal women,
    • Men: on adequate testosterone replacement therapy: normal male reference range,
  • Blood urea nitrogen (BUN), creatinine, (AST), alanine transaminase (ALT) not elevated,
  • For women,

    • Negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of screening (additional urine pregnancy test will be conducted prior to drug administration),
    • Not breastfeeding and not pregnant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Experimental: kisspeptin, GnRH

    • Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.

    Drug: kisspeptin 112-121 · Drug: GnRH

Interventions

06

What researchers measure

Primary outcomes

  1. Average Change in Luteinizing Hormone (LH) Pulse Amplitude in Response to Kisspeptin

    Change in LH amplitude before, during and after kisspeptin administration

    Time frame: 52 hours

Secondary outcomes

  1. Average Change in LH Pulse Frequency in Response to Kisspeptin

    Change in LH frequency before and after kisspeptin administration

    Time frame: 52 hours

07

Results

Posted Aug 26, 2026

Participant flow

Boston area. 18 participants were consented and screened for eligibility between 5/2019 and 11/2022.

Participant flow — Overall Study
MilestoneExperimental: Kisspeptin, GnRH
Started18
Completed7
Not completed11

Outcome measures

PrimaryAverage Change in Luteinizing Hormone (LH) Pulse Amplitude in Response to Kisspeptin

Change in LH amplitude before, during and after kisspeptin administration

Time frame:
52 hours
Reported as:
Mean · IU/L
Average Change in Luteinizing Hormone (LH) Pulse Amplitude in Response to Kisspeptin
IU/LExperimental: Kisspeptin, GnRH
Before vs. During0.35 ± 0.43
Before vs. After0.19 ± 0.30
SecondaryAverage Change in LH Pulse Frequency in Response to Kisspeptin

Change in LH frequency before and after kisspeptin administration

Time frame:
52 hours
Reported as:
Mean · # pulses/hour
Average Change in LH Pulse Frequency in Response to Kisspeptin
# pulses/hourExperimental: Kisspeptin, GnRH
Average Change in LH Pulse Frequency in Response to Kisspeptin0.17 ± 0.27

Adverse events

Collected over From time of study consent until removal from study participation (approximately 3 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Kisspeptin, GnRH0/18 (0%)1/18 (5.6%)6/18 (33.3%)
Most frequent serious events
Most frequent serious events
EventExperimental: Kisspeptin, GnRH
Rhabdomyolysis after completion of study visitsMusculoskeletal and connective tissue disorders1/18
Most frequent other events
Most frequent other events
EventExperimental: Kisspeptin, GnRH
FatigueGeneral disorders2/18
Hot flashesVascular disorders1/18
Skin infectionInfections and infestations1/18
DizzinessNervous system disorders1/18
DyspneaRespiratory, thoracic and mediastinal disorders1/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental: Kisspeptin, GnRH
<=18 years2
Between 18 and 65 years16
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Kisspeptin, GnRH
Female8
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Kisspeptin, GnRH
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race1
Unknown or Not Reported1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: Kisspeptin, GnRH
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported3
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Aug 2025, 75 months.

Results were first posted in Aug 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2020
First posted
Dec 2, 2020
StartActual
May 3, 2019
Primary completionActual
Aug 31, 2025
CompletionActual
Aug 31, 2025
Results first posted
Aug 26, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04648969
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Massachusetts General Hospital; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
Dec 2, 2020
Start date
May 3, 2019
Primary completion
Aug 31, 2025
Completion
Aug 31, 2025
Results posted
Aug 26, 2026
Last update
Aug 26, 2026

Study contacts

Stephanie Seminara
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KISS1 protein, human · Gonadotropin-Releasing Hormone

Start the discussion